Neurotrope 10-K 26 Mar 15 2014 FY Annual report Financial data

Document_And_Entity_Informatio

Document And Entity Information (USD $)	12 Months Ended
	Dec. 31, 2014	Mar. 19, 2015	Jun. 30, 2014
Document Information [Line Items]
Document Type	10-K
Amendment Flag	FALSE
Document Period End Date	31-Dec-14
Document Fiscal Year Focus	2014
Document Fiscal Period Focus	FY
Entity Registrant Name	Neurotrope, Inc.
Entity Central Index Key	1513856
Current Fiscal Year End Date	-19
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Filer Category	Smaller Reporting Company
Entity Public Float			$560,429
Trading Symbol	NTRP
Entity Common Stock, Shares Outstanding		26,795,258

Consolidated_Balance_Sheets

Consolidated Balance Sheets (USD $)	Dec. 31, 2014	Dec. 31, 2013
CURRENT ASSETS
Cash and cash equivalents	$8,010,357	$15,211,744
Prepaid expenses	97,073	87,059
TOTAL CURRENT ASSETS	8,107,430	15,298,803
Fixed Assets, net of accumulated depreciation	53,618	0
TOTAL ASSETS	8,161,048	15,298,803
CURRENT LIABILITIES
Accounts payable	778,753	119,608
Accrued expenses	310,435	37,029
Accounts payable and accrued expenses - related party	200,000	251,779
TOTAL CURRENT LIABILITIES	1,289,188	408,416
Commitments and contingencies
Convertible redeemable preferred stock, Series A, $.0001 par value, 50,000,000 shares authorized; 21,363,000 and 23,000,000 shares issued and outstanding at December 31, 2014 and 2013, respectively. Liquidation preference of $21,363,000 plus dividends accruable at 8% per annum of $2,687,835 as of December 31, 2014 and Liquidation preference of $23,000,000 plus dividends accruable at 8% per annum of $1,023,616 at December 31, 2013.	18,524,163	19,943,572
SHAREHOLDERS' DEFICIT
Common stock - 300,000,000 shares authorized, $.0001 par value; 24,034,094 issued and outstanding at December 31, 2014; 21,740,006 shares issued and outstanding at December 31, 2013	2,403	2,174
Additional paid-in capital	6,627,983	3,974,007
Accumulated deficit	-18,282,689	-9,029,366
TOTAL SHAREHOLDERS' DEFICIT	-11,652,303	-5,053,185
TOTAL LIABILITIES AND SHAREHOLDERS' DEFICIT	$8,161,048	$15,298,803

Consolidated_Balance_Sheets_Pa

Consolidated Balance Sheets [Parenthetical] (USD $)	Dec. 31, 2014	Dec. 31, 2013
Common stock, par value (in dollars per share)	$0.00	$0.00
Common stock, shares authorized	300,000,000	300,000,000
Common stock, shares issued	24,034,094	21,740,006
Common stock, shares outstanding	24,034,094	21,740,006
Series A Convertible Redeemable Preferred Stock [Member]
Preferred stock, par value (in dollars per share)	$0.00	$0.00
Preferred stock, shares authorized	50,000,000	50,000,000
Preferred stock, shares issued	21,363,000	23,000,000
Preferred stock, shares outstanding	21,363,000	23,000,000
Preferred Stock, Liquidation Preference, Value (in dollars)	$21,363,000	$23,000,000
Dividends Payable Percentage (in percentage)	8.00%	8.00%
Dividends Payable (in dollars)	$2,687,835	$1,023,616

Consolidated_Statements_of_Ope

Consolidated Statements of Operations (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
OPERATING EXPENSES:
Research and development - related party	$2,223,643	$1,367,644
Research and development	1,242,706	0
General and administrative - related party	108,693	1,446,986
General and administrative	4,488,415	1,653,208
Stock-based compensation - related party	252,868	2,854,745
Stock-based compensation	950,795	268,199
TOTAL OPERATING EXPENSES	9,267,120	7,590,782
OTHER INCOME:
Interest income	13,797	1,378
Net loss before income taxes	-9,253,323	-7,589,404
Provision for income taxes	0	0
Net loss	-9,253,323	-7,589,404
Preferred Stock dividends	-1,664,219	-1,023,616
Net loss attributable to common shareholders	($10,917,542)	($8,613,020)
PER SHARE DATA:
Basic and diluted loss per common share (in dollars per share)	($0.49)	($0.40)
Basic and diluted weighted average common shares outstanding (in shares)	22,106,516	21,702,415

Consolidated_Statement_of_Chan

Consolidated Statement of Changes in Shareholders' Deficit (USD $)	Total	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Deficit [Member]
Balance at Dec. 31, 2012	($1,437,793)	$2,169	$0	($1,439,962)
Balance (in shares) at Dec. 31, 2012		21,690,406
Stock based compensation	3,122,944	0	3,122,944	0
Issuance of common stock warrants	806,428	0	806,428	0
Issuance of common stock for consulting services	44,640	5	44,635	0
Issuance of common stock for consulting services (in shares)		49,600
Net loss	-7,589,404	0	0	-7,589,404
Balance at Dec. 31, 2013	-5,053,185	2,174	3,974,007	-9,029,366
Balance (in shares) at Dec. 31, 2013		21,740,006
Conversion of Series A preferred stock to common stock	1,419,410	164	1,419,246	0
Conversion of Series A preferred stock to common stock (in shares)		1,637,000
Stock based compensation	1,203,663	0	1,203,663	0
Issuance of common stock for consulting services	25,000	4	24,996
Issuance of common stock for consulting services (in shares)		43,860
Exercise of common stock warrants	6,132	61	6,071
Exercise of common stock warrants (in shares)		613,228
Net loss	-9,253,323	0	0	-9,253,323
Balance at Dec. 31, 2014	($11,652,303)	$2,403	$6,627,983	($18,282,689)
Balance (in shares) at Dec. 31, 2014		24,034,094

Consolidated_Statements_of_Cas

Consolidated Statements of Cash Flows (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	($9,253,323)	($7,589,404)
Adjustments to reconcile net loss to net cash used by operating activities
Stock based compensation	1,203,663	3,122,944
Consulting services paid by issuance of common stock	25,000	44,640
Depreciation expense	1,325	0
Change in assets and liabilities
Increase in prepaid expenses	-10,014	-87,059
Decrease in accounts payable and accrued expenses - related party	-51,779	-988,857
Increase (decrease) in accounts payable	659,146	-72,734
Increase in accrued expenses	273,406	37,029
Total adjustments	2,100,747	2,055,963
Net Cash Used in Operating Activities	-7,152,576	-5,533,441
CASH FLOWS FROM INVESTING ACTIVITIES
Purchase of property and equipment	-54,943	0
CASH FLOWS FROM FINANCING ACTIVITIES
Issuance of preferred stock, net of transaction costs	0	20,750,000
Proceeds from exercise of common stock warrants	6,132	0
Repayment of advances from related party	0	-4,815
Net Cash Provided by Financing Activities	6,132	20,745,185
NET (DECREASE) INCREASE IN CASH	-7,201,387	15,211,744
CASH AT BEGINNING OF YEAR	15,211,744	0
CASH AT END OF YEAR	$8,010,357	$15,211,744
DISCLOSURE OF NON-CASH FINANCING ACTIVITIES:
Conversion of Series A convertible redeemable preferred stock to common stock	1,419,410	0

Organization_and_Nature_of_Pla

Organization and Nature of Planned Business:	12 Months Ended
	Dec. 31, 2014
GENERAL ORGANIZATION AND BUSINESS [Abstract]
Nature of Operations [Text Block]	Note 1 – Organization and Nature of Planned Business:
	References in these notes to the consolidated financial statements to “Neurotrope, Inc.,” “we,” “us,” “our Company” refer to Neurotrope, Inc. and its consolidated subsidiary Neurotrope Bioscience, Inc. (“Neurotrope BioScience”). Neurotrope BioScience was incorporated in Delaware on October 31, 2012. Neurotrope BioScience was formed to advance new therapeutic and diagnostic technologies in the field of neurodegenerative disease, primarily Alzheimer’s disease (“AD”). Neurotrope BioScience is collaborating with the Blanchette Rockefeller Neurosciences Institute (“BRNI”), a related party, in this process. The exclusive rights to the licensed technology transferred to the Company on February 28, 2013 (see Note 6).
	On August 23, 2013, a wholly-owned subsidiary of Neurotrope, Inc. (formerly “BlueFlash Communications, Inc.”), Neurotrope Acquisition, Inc., a corporation formed in the State of Nevada on August 15, 2013 merged (the “Reverse Merger”) with and into Neurotrope BioScience. Neurotrope BioScience was the surviving corporation in the Reverse Merger and became the Company’s wholly-owned subsidiary. All of the outstanding Neurotrope BioScience common stock was converted into shares of Neurotrope, Inc. common stock on a one-for-one basis.
	The transaction was accounted for as a reverse merger and recapitalization with Neurotrope BioScience as the acquirer for financial reporting purposes and Neurotrope, Inc. as the acquired company. Consequently, the assets and liabilities and the operations that are reflected in the historical financial statements are those of Neurotrope BioScience and are recorded at the historical cost basis of Neurotrope BioScience, and the consolidated financial statements after completion of the Reverse Merger include the assets and liabilities of Neurotrope BioScience and Neurotrope, Inc., and the historical operations of Neurotrope, Inc. and Neurotrope BioScience from the closing date.
	As a result of the Reverse Merger, Neurotrope, Inc. discontinued its pre-Reverse Merger business and acquired the business of Neurotrope BioScience, which it is continuing to operate through Neurotrope BioScience. The common stock of Neurotrope, Inc. is traded under the ticker symbol “NTRP.”

Going_Concern

Going Concern:	12 Months Ended
	Dec. 31, 2014
Going Concern [Abstract]
Going Concern [Text Block]	Note 2 – Going Concern:
	The consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. As shown in the consolidated financial statements, we have generated no revenues to-date, have incurred substantial losses during the Company’s development stage and have substantial contractual commitments pursuant to various agreements to which we are a party.
	Our ability to continue existence is dependent upon our continuing efforts to obtain additional financing to carry out our business plan during the development stage. We intend to fund our operations through equity and/or debt financing arrangements and any revenues generated in the future. However, there can be no assurance that these arrangements, if any, will be sufficient to fund our ongoing capital expenditures, working capital, and other cash requirements. The outcome of these matters cannot be predicted at this time.
	There can be no assurance that any additional financings will be available to us on satisfactory terms and conditions, if at all. These conditions raise substantial doubt as to our ability to continue as a going concern.
	The consolidated financial statements do not include any adjustments related to the recoverability or classification of asset-carrying amounts or the amounts and classification of liabilities that may result should we be unable to continue as a going concern.

Summary_of_Significant_Account

Summary of Significant Accounting Policies:	12 Months Ended
	Dec. 31, 2014
SUMMARY OF SIGNIFICANT ACCOUNTING PRACTICES [Abstract]
Significant Accounting Policies [Text Block]	Note 3 - Summary of Significant Accounting Policies:
	Recently Adopted Accounting Standards:
	In June 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update No. 2014-10, Development Stage Entities (Topic 915) – Elimination of Certain Financial Reporting Requirements, Including an Amendment to Variable Interest Entities Guidance in Topic 810, Consolidation (“ASU 2014-10”). ASU 2014-10 eliminates the concept of a development stage entity in its entirety from current accounting guidance. The new guidance eliminates the requirements for development stage entities to (i) present inception-to-date information in the statement of operations, stockholders’ equity and cash flows, (ii) label the financial statements as those of a development stage entity, (iii) disclose a description of the development stage activities in which the entity is engaged, and (iv) disclose in the first year in which the entity is no longer a development stage entity that in prior years it had been in the development stage. ASU 2014-10 is effective prospectively for public entities for annual reporting periods beginning after December 15, 2015, and interim periods within those annual periods; however, early adoption is permitted. The Company elected to adopt ASU 2014-10 as permitted, for the financial statements ended December 31, 2014 and, accordingly, has not included the inception-to-date disclosures and other previously required disclosures for development stage entities.
	Use of Estimates:
	The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
	Reclassifications:
	Certain reclassifications have been made to the 2013 financial statements to conform to the consolidated 2014 financial statement presentation. These reclassifications had no effect on net loss or cash flows as previously reported.
	Cash and Cash Equivalents:
	The Company considers all highly liquid temporary cash investments with an original maturity of three months or less when purchased to be cash equivalents. At December 31, 2014, the Company’s cash balances may exceed the current insured amounts under the Federal Deposit Insurance Corporation.
	Property and Equipment:
	Property and equipment is capitalized and depreciated on a straight line basis over the useful life of the asset, which is deemed to be between three and ten years. Property and equipment consist of the following at December 31:
		2014		2013
	Property and equipment	$	54,943	$	0
	Accumulated depreciation	$	-1,325	$	0
	Property and equipment, net	$	53,618	$	0
	Depreciation expense for the year ended December 31, 2014 was $1,325 compared to $0 for 2013.
	Research and Development Costs:
	All research and development costs, including costs to maintain or expand the Company’s patent portfolio that do not meet the criteria for capitalization are expensed when incurred. FASB ASC Topic 730 requires companies involved in research and development activities to capitalize non-refundable advance payments for such services pursuant to contractual arrangements because the right to receive those services represents an economic benefit. Such capitalized advances will be expensed when the services occur and the economic benefit is realized. There were no capitalized research and development services at December 31, 2014 and 2013.
	Income Taxes:
	Income taxes are provided for the tax effects of transactions reported in the financial statements and consist of taxes currently due and deferred taxes. Deferred taxes are recognized for differences between the bases of assets and liabilities for financial statement and income tax purposes and the tax effects of net operating loss and other carryforwards. The deferred tax assets and liabilities represent the future tax consequences of those differences and carryforwards, which will either be taxable or deductible when the related assets, liabilities or carryforwards are recovered or settled. Deferred tax assets are reduced by a valuation allowance when, based on the weight of available evidence, it is more likely than not that some portion or all of the deferred tax assets will not be realized.
	The Company applies the provisions of FASB ASC 740-10, Accounting for Uncertain Tax Positions, which clarifies the accounting for uncertainty in income taxes recognized in an enterprise’s financial statements and prescribes a recognition threshold and measurement process for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. The standard also provides guidance on de-recognition, classification, interest and penalties, and accounting in interim periods, disclosure and transitions.
	The Company has concluded that there are no significant uncertain tax positions requiring recognition in the accompanying financial statements. The tax period that is subject to examination by major tax jurisdictions is from October 31, 2012 (inception) through December 31, 2014.
	In the event the Company was to receive an assessment for interest and/or penalties, it will be classified in the financial statements as selling, general and administrative expense when assessed.
	Risks and Uncertainties:
	The Company operates in an industry that is subject to rapid technological change, intense competition and significant government regulation. The Company’s operations are subject to significant risk and uncertainties including financial, operational, technological, regulatory and other risk. Such factors include, but are not necessarily limited to, the results of clinical testing and trial activities, the ability to obtain regulatory approval, the ability to obtain favorable licensing, manufacturing or other agreements for its product candidates and the ability to raise capital to achieve strategic objectives.
	Stock Compensation:
	The Company accounts for stock-based awards to employees in accordance with applicable accounting principles, which requires compensation expense related to share-based transactions, including employee stock options, to be measured and recognized in the financial statements based on a determination of the fair value of the stock options. The grant date fair value is determined using the Black-Scholes-Merton (“Black-Scholes”) pricing model. For all employee stock options, we recognize expense over the employee’s requisite service period (generally the vesting period of the equity grant). The Company’s option pricing model requires the input of highly subjective assumptions, including the expected stock price volatility, expected term, and forfeiture rate. Any changes in these highly subjective assumptions significantly impact stock-based compensation expense.
	Options awarded to purchase shares of common stock issued to non-employees in exchange for services are accounted for as variable awards in accordance with applicable accounting principles. Such options are valued using the Black-Scholes option pricing model.

Contractual_Commitments

Contractual Commitments:	12 Months Ended
	Dec. 31, 2014
Contractual Commitments [Abstract]
Contractual Commitments [Text Block]	Note 4 – Contractual Commitments:
	From January 1, 2013 through February 28, 2013, Neurotrope BioScience compensated its former President under an independent contractor agreement at the rate of $20,833 per month. On February 25, 2013, Neurotrope BioScience executed a four-year employment agreement, effective March 1, 2013, with its former President (the “Employment Agreement”). The Employment Agreement provided for an annual salary of $250,000 and an annual bonus of $50,000, which would have increased to an annual salary of $300,000 and an annual bonus of $100,000 effective as of the later of (a) February 28, 2015 or (b) the closing by the Company of a Series B Preferred Stock financing as described in Note 6 below. Effective as of July 16, 2014, the former President’s employment as Chief Executive Officer and President of Neurotrope BioScience and the Company was terminated.
	In connection with his termination, effective as of July 16, 2014, Neurotrope BioScience and its former President entered into a separation agreement and general release on October 9, 2014 (the “Separation Agreement”).
	The Separation Agreement states that Neurotrope BioScience will pay or provide to the former President the following: (a) $2,684 within three days of the execution of the Separation Agreement by him, representing reimbursement of business expenses; (b) a lump sum equal to the total gross amount of $233,000 (less all applicable income and employment taxes and other required or elected withholdings, for which a Form W-2 will be issued to him); (c) a gross amount of $25,478 (less all applicable income and employment taxes and other required or elected withholdings) for his accrued, unused vacation; (d) reimbursement for the cost of continuing his current health care insurance in the same amount as the net reimbursement amounts paid to him on a monthly basis immediately prior to July 16, 2014 ($2,974 per month) until the earlier of the date on which he becomes eligible for medical insurance coverage with a new employer or July 16, 2015; (e) director’s and officer’s insurance coverage covering his actions while a director and/or officer of Neurotrope BioScience until July 16, 2020; and (f) $17,000 for reimbursement of his attorneys fees. In addition, the parties agreed that his ownership of any common shares of the company is not affected by the Separation Agreement and that any equity awards he received pursuant to the 2013 Equity Incentive Plan will be governed exclusively by the terms of such plan. Approximately $282,000 was paid to him pursuant to the Separation Agreement in 2014.
	Effective February 28, 2013, the Company executed an agreement with Ramat Consulting Corp. (“Ramat”), a related party to the Company’s current President and CEO Charles S. Ramat, for consulting services, including business development and marketing consulting, for a five-year period, subject to annual renewals thereafter. The Ramat agreement was amended on February 2, 2015 to add Mr. Ramat’s duties as the Company’s President and CEO. No other changes were made. Ramat's annual fee is $50,000, payable in monthly installments of $4,167, plus pre-approved travel and other reimbursable expenses. Ramat was issued a non-qualified option, with a term of ten years, to purchase 300,000 shares of common stock of the Company at an exercise price of $1.00 per share. The option vested with respect to 20% of the shares as of February 28, 2013, and the balance vest on a daily basis over the four-year period beginning on February 28, 2013. Vested options will terminate, to the extent not previously exercised, upon the occurrence of the first of the following events: (a) ten years from the date of grant; (b) the expiration of one year from the date of death or the termination of optionee as a service provider by reason of disability; or (c) the expiration of twelve months from the date of termination of optionee’s service as a service provider for any reason whatsoever other than termination of service for death or disability. An entity related to Ramat purchased 1,000,000 shares of the Company’s Series A Preferred Stock on the effective date of the consulting agreement described in this paragraph.
	On October 1, 2013, the Company canceled its agreement with MCMS and executed a four-year employment agreement, effective October 1, 2013, with Robert Weinstein, its current Executive Vice President, Chief Financial Officer, Treasurer and Secretary. This agreement provides for an annual salary of $240,000, which shall increase to an annual salary of $275,000 beginning January 1, 2015. In addition, the agreement provides for a $35,000 bonus for the year ended December 31, 2013, a $50,000 bonus for the year ending December 31, 2014 and a targeted bonus of 50% of base salary for all subsequent years. On October 1, 2013, the Company’s Board of Directors (the “Board”) granted an incentive stock option to Mr. Weinstein under the Company’s 2013 Equity Incentive Plan (the “2013 Plan”) to purchase 650,000 shares of the Company’s common stock, with a term of ten years, exercisable at $1.00 per share. These options vest 25% per year over four years, with accelerated vesting of 25% upon a termination without cause or for good reason.
	On January 16, 2014, the Company executed a four-year employment letter with Neurotrope BioScience’s Vice President – Commercial Operations. This employment letter provides for an annual salary of $210,000 which shall increase at the discretion of the Company’s Compensation Committee. In addition, the employment letter provides for a discretionary bonus of up to 35% of base salary for all years. On January 23, 2014, the Board granted an incentive stock option to its Vice President – Commercial Operations under the 2013 Plan to purchase 100,000 shares of the Company’s common stock, with a term of ten years, exercisable at $1.76 per share. These options vest 20% per year over five years. Vested options will terminate, to the extent not previously exercised, upon the occurrence of the first of the following events: (a) ten years from the date of grant; or (b) the expiration of one year from the date of death, disability or the termination of employment.
	On January 22, 2014, the Company executed a four-year employment agreement with Neurotrope BioScience’s Vice President and Chief Medical Officer. This agreement provided for an annual salary of $210,000. In addition, the employment agreement provided for a discretionary bonus of up to 35% of base salary for all years. On January 23, 2014, the Board granted an incentive stock option to its former Vice President and Chief Medical Officer under the 2013 Plan to purchase 125,000 shares of the Company’s common stock, with a term of ten years, exercisable at $1.76 per share. These options vest 25% per year over four years, with accelerated vesting of 25% upon a termination without cause or for good reason. On October 31, 2014, the Company terminated Neurotrope BioScience’s former Vice President and Chief Medical Officer without cause. Upon termination without cause and conditioned upon the execution of a release, he received severance and accelerated vesting of a portion of his incentive stock option to purchase 31,250 shares of the Company’s common stock. Approximately $217,000 was accrued for this severance arrangement in 2014 and paid in February 2015.
	On June 1, 2014, the Company executed a four-year employment letter, with Neurotrope BioScience’s Executive Director – Pharmacology. This employment letter provides for an annual salary of $180,000 which shall increase at the discretion of the Company’s Compensation Committee. In addition, the employment letter provides for a discretionary bonus of up to 25% of base salary for all years. On July 16, 2014, the Board granted an incentive stock option to the Executive Director for the purchase of 50,000 shares of the Company’s common stock (see Note 10 – “Stock Options” for details).
	On July 16, 2014, the Board appointed Charles S. Ramat and Paul E. Freiman to serve as Co-Chief Executive Officers, on an interim basis, of the Company and of Neurotrope BioScience. Mr. Freiman has served on the Board since October 18, 2013, and was appointed Co-Chairman of the Board on June 13, 2014. Mr. Ramat was elected to the Board on June 13, 2014 and was immediately appointed Co-Chairman of the Board.
	In consideration of the services to be provided by Mr. Freiman and Mr. Ramat to the Company as Co-Chief Executive Officers, the Company agreed to pay each of them consulting fees in the amount of $20,000 per month for a term not to exceed six months, which fees would be reduced upon the employment of a permanent Chief Executive Officer to $10,000 per month for two months to aid in the transition of responsibilities to the new Chief Executive Officer. In addition, on July 23, 2014, Messrs. Freiman and Ramat were each granted non-qualified options to purchase 400,000 shares of the Company’s common stock for their roles as directors, Co-Chairmen of the Board and Co-Chief Executive Officers. Options to purchase 200,000 shares have an exercise price of $1.11 per share, or 110% of the Company’s last trading price on July 23, 2014 and were fully vested upon grant. Options to purchase the remaining 200,000 shares have an exercise price of $2.22 per share based upon two times the exercise price of $1.11 per share and vest on a daily basis up to 25% per year through July 23, 2018. See below regarding further changes to Messrs. Ramat and Freiman’s roles with the Company.
	On September 4, 2014, the Company entered into a long-term lease for 4,000 square feet of office space in Newark, New Jersey. The lease commenced September 1, 2014 and expires December 1, 2017 and has two (2) one-year renewal options. The base rent is payable, commencing December 1, 2014, at an annual rate of $88,000 with no increases during the lease term and renewal terms. In addition, commencing September 1, 2014, the Company is obligated to pay its share of common area charges. The Company is amortizing the total base rent due over 39 months and has expensed $28,927 for 2014.
	On September 12, 2014, the Board elected Mr. Ramat to be the Company’s President and Chief Executive Officer and Mr. Freiman to be the Company’s Chairman of the Board. In consideration of the services that Mr. Ramat will provide to the Company as President and CEO, the Company agreed to pay Mr. Ramat a consulting fee of $400,000 per year with a bonus opportunity of up to 50% of his consulting fee after one (1) year of service, which arrangement may be terminated by either party on 60 days’ notice. Mr. Ramat’s consulting fee replaces the $20,000 per month consulting fee of July 16, 2014. Mr. Freiman’s compensation remains at $20,000 per month as Chairman of the Board. In addition to his salary for services as President and Chief Executive Officer of the Company, Mr. Ramat will continue to be paid the consulting fees under a Consulting Agreement with the Company pursuant to which he receives $50,000 per year.
	In addition, on September 12, 2014, Messrs. Ramat and Freiman were granted non-qualified options to purchase 250,000 and 50,000 shares of the Company’s common stock, respectively, which have an exercise price of $0.60 per share, are fully vested upon grant, and have a ten-year life.
	As of November 1, 2014, Neurotrope BioScience entered into an employment agreement for one (1) year with provisions for automatic renewals, with a new Executive Vice President, Development and Chief Medical Officer. This agreement provides for an annual salary of $325,000 which shall increase at the discretion of the Company’s President. In addition, the employment agreement provides for a signing bonus of $102,083 in total, payable $8,507 monthly (if employed during the applicable payment cycle) and a discretionary bonus of up to 50% of base salary. In connection with his employment and as of his date of hire, the Company’s Compensation Committee authorized a grant of a non-qualified stock option to Neurotrope BioScience’s new Executive Vice President and Chief Medical Officer under the 2013 Plan to purchase 250,000 shares of the Company’s common stock, with a term of ten years, exercisable at $0.71 per share. These options vest 20% per year over five years commencing November 1, 2015.

Collaborative_Agreements

Collaborative Agreements:	12 Months Ended
	Dec. 31, 2014
Collaborative Agreements [Abstract]
Collaborative Agreements [Text Block]	Note 5 – Collaborative Agreements:
	On May 12, 2014, the Company entered into a license agreement (the “Stanford Agreement”) with The Board of Trustees of The Leland Stanford Junior University (“Stanford”), pursuant to which Stanford has granted to the Company a revenue-bearing, world-wide right and exclusive license, with the right to grant sublicenses (on certain conditions), under certain patent rights and related technology for the use of bryostatin structural derivatives, known as “bryologs,” for use in the treatment of central nervous system disorders, lysosomal storage diseases, stroke, cardioprotection and traumatic brain injury, for the life of the licensed patents.
	Pursuant to the Stanford Agreement, in 2014, the Company paid Stanford a total of $60,850, of which $48,564 was expensed by the Company in 2014. The Company is also obligated to pay Stanford: (a) a $10,000 annual license maintenance fee; (b) milestone payments in the aggregate amount of up to $3,700,000 upon the achievement of certain product development events commencing upon the filing of the first IND application through approval of an applicable product; and (c) low single-digit royalties on net sales of licensed products.
	Each party has the right to terminate the Stanford Agreement for an uncured material breach of the other party. Additionally, the Company may terminate the Stanford Agreement at any time upon 60 days’ written notice to Stanford.
	On May 15, 2014, the Company entered into an agreement with a contract research organization (“CRO”) to conduct a clinical trial relating to AD. The Company has agreed to pay fees to the CRO totaling $715,159, based upon signing of the agreement and the CRO achieving certain clinical trial milestones, plus reasonable out-of-pocket expenses. On November 19, 2014, the CRO agreement was amended, requiring the Company to pay a reduced amount totaling $657,238. The Company has incurred a total of $417,877 in fees, all of which are included in the balance sheet as payables as of December 31, 2014.
	On July 14, 2014, Neurotrope BioScience entered into an Exclusive License Agreement (the “Mount Sinai Agreement”) with Icahn School of Medicine at Mount Sinai (“Mount Sinai”). Pursuant to the Mount Sinai Agreement, Mount Sinai granted Neurotrope BioScience a revenue-bearing, world-wide right and (a) exclusive license, with the right to grant sublicenses (on certain conditions), under Mount Sinai’s interest in certain joint patents held by the Company and Mount Sinai (the “Joint Patents”) as well as in certain results and data (the “Data Package”) and (b) non-exclusive license, with the right to grant sublicenses on certain conditions, to certain technical information, both relating to the diagnostic, prophylactic or therapeutic use for treating diseases or disorders in humans relying on activation of PKCepsilon, which includes Niemann-Pick C Disease (the “Mount Sinai Field of Use”). The Mount Sinai Agreement allows Neurotrope BioScience to research, discover, develop, make, have made, use, have used, import, lease, sell, have sold and offer certain products, processes or methods that are covered by valid claims of Mount Sinai’s interest in the Joint Patents or an Orphan Drug Designation Application covering the Data Package (the “Mount Sinai Licensed Products”) in the Mount Sinai Field of Use.
	Pursuant to the Mount Sinai Agreement, Neurotrope BioScience is obligated to pay a $25,000 license initiation fee to Mount Sinai. Neurotrope BioScience is also obligated to pay Mount Sinai (a) a $10,000 annual license maintenance fee until minimum royalty payments are due, (b) milestone payments in the aggregate amount of up to $3,500,000 upon the achievement of certain product development events relating to the approval of a licensed product in the United States and other jurisdictions, (c) low single-digit royalties on net sales of the Mount Sinai Licensed Products, and (d) a portion of sublicense fees ranging from a significant double-digit percentage based on sublicensing before completion of in vivo proof-of-concept experiments to a mid-single digit percentage after product approval. In 2014, the Company paid Mount Sinai $25,000, which represents the license initiate fee described above. Of this $25,000, the Company expensed $11,458 in 2014. Also in 2014, the Company accrued $12,000 as an expense to Mount Sinai for certain consulting services that did not get paid in 2014.
	Each party has the right to terminate the Mount Sinai Agreement for an uncured material breach of the other party. Additionally, Neurotrope BioScience may terminate the Agreement at any time upon 60 days’ written notice to Mount Sinai. Further, upon termination, Neurotrope BioScience may continue to sell any and all licensed products, provided that Neurotrope BioScience will pay Mount Sinai a reduced royalty for licensed products that are indicated as therapeutics or diagnostics for Niemann Pick disease which are sold following the termination of the Mount Sinai Agreement.
	The term of the Mount Sinai Agreement began upon signing and will expire with respect to each Mount Sinai Licensed Product on a Mount Sinai Licensed Product-by-Mount Sinai Licensed Product basis and country-by-country basis, from first commercial sale until the later of: (a) expiration of the last to expire Joint Patent Rights covering such Mount Sinai Licensed Product in such country; (b) expiration of any market exclusivity period granted by a regulatory agency with respect to such Mount Sinai Licensed Product in such country; or (c) ten years after the first commercial sale of such Mount Sinai Licensed Product in such country.

Related_Party_Transactions_and

Related Party Transactions and Licensing / Research Agreements:	12 Months Ended
	Dec. 31, 2014
Related Party Transactions [Abstract]
Related Party Transactions Disclosure [Text Block]	Note 6 – Related Party Transactions and Licensing / Research Agreements:
	Two directors of the Company, James Gottlieb and William Singer, are also directors of BRNI. One of those directors, Mr. Singer, is the president of BRNI. BRNI is a stockholder of a corporation, Neuroscience Research Ventures, Inc. (“NRVI”), which owned 37.6% of the Company's outstanding common stock as of December 31, 2014.
	Effective October 31, 2012, Neurotrope BioScience executed a Technology License and Services Agreement with BRNI, a related party, and NRV II, LLC, another affiliate of BRNI (the “BRNI License Agreement”). Under the terms of the BRNI License Agreement, BRNI provides research services and granted Neurotrope BioScience the exclusive and nontransferable license right to certain patent and intellectual property which became effective upon the Neurotrope BioScience’s completion of a Series A Preferred Stock financing generating net proceeds to Neurotrope BioScience of at least $8,000,000 on February 28, 2013. The BRNI License Agreement terminates on the later of the date (a) the last of the licensed patent expires, is abandoned, or is declared unenforceable or invalid or (b) the last of the intellectual property enters the public domain.
	The research services provided under the BRNI License Agreement commenced on April 2, 2012. The BRNI License Agreement requires Neurotrope BioScience to reimburse BRNI for services rendered (the “Services Reimbursement”) on a pro-rated, 30-month basis, with respect to the period of time elapsed from April 2, 2012 through the date of the Series A Preferred Stock financing on February 28, 2013. BRNI charged Neurotrope BioScience $266,666 from January 1, 2013 to February 28, 2013.
	After the initial Series A Preferred Stock financing, the BRNI License Agreement requires Neurotrope BioScience to enter into scope of work agreements with BRNI as the preferred service provider, for any research and development services or other related scientific assistance and support services. Neurotrope BioScience is not permitted to engage any other person other than BRNI to perform research or development services or other related scientific assistance without prior written consent of BRNI, except under certain circumstances. BRNI and Neurotrope may agree to have a third party provide services identical or similar to such services to Neurotrope in the case where BRNI is demonstrably unable to do so or such third party is demonstrably in a superior position to do so.
	In addition, the BRNI License Agreement requires the Company to pay BRNI a “Fixed Research Fee,” commencing the date that the Company completes a Series B Preferred Stock financing resulting in net proceeds of at least $25,000,000 (the “Series B Financing”). The fixed research fee is (a) a pro-rata amount of $1,000,000 in the year the Company completes such financing (b) $1,000,000 per year for five calendar years subsequent to such financing and (c) an annual fixed research fee in an amount to be negotiated and agreed upon no later than 90 days prior to the end of the fifth calendar year following the completion of such financing to be paid with respect to each remaining calendar year during the term of the BRNI License Agreement. The Company has not yet completed this Series B Financing (see Note 9) and, accordingly, no such fees are due.
	The BRNI License Agreement also requires the payment of royalties ranging between 2% and 5% of the Company’s revenues generated from the licensed patents and other intellectual property, dependent upon the percentage ownership that NRVI holds in the Company. Under the BRNI License Agreement, the Company is required to prepay royalty fees at a rate of 5% of all investor funds raised in the Series A or Series B Preferred Stock financings or any subsequent rounds of financing prior to a public offering, less commissions. On March 25, 2013, the Company prepaid $409,549 in royalties under the BRNI License Agreement and paid the remainder due of $60,349 in July 2013 relating to the May 7, 2013 Series A Preferred Stock financing. On August 29, 2013, the Company paid $520,252 in prepaid royalties relating to the August 23, 2013 Series A Preferred Stock financing. On October 4, 2013, the Company paid $48,600 in prepaid royalties relating to the Series A Preferred Stock financing. These royalties were expensed in “general and administrative expenses – related party” in the statement of operations as there is no guarantee that sales will be achieved and royalties warranted.
	Effective August 28, 2013, Neurotrope BioScience signed a statement of work (“SOW”) with BRNI pursuant to the BRNI License Agreement for the further development of its Alzheimer’s disease (“AD”) diagnostic product. Pursuant to the SOW, Neurotrope BioScience paid BRNI a total of $1,645,470 in 12 equal monthly installments of $137,123, payable on the first business day of each month. These payments are for operating expenses associated with BRNI’s diagnostic laboratories. Operating expenses that are incurred in excess of this total amount are the responsibility of BRNI unless prior approval is obtained from Neurotrope BioScience. The SOW may be extended if BRNI provides Neurotrope BioScience with two months advanced notice that the SOW objectives are not met within the initial 12 month period. As of December 31, 2014, BRNI did provide Neurotrope BioScience with the requisite notice to extend the term of the SOW. The parties have negotiated the terms of such extension.
	Subsequent to the year ended December 31, 2014 and effective as of October 31, 2012, Neurotrope BioScience entered into an Amended and Restated Technology License and Services Agreement with BRNI and NRV II, LLC on February 4, 2015 (the “Amended and Restated BRNI License”). The agreement further amended and restated that certain Technology License and Services Agreement executed as of October 31, 2012. Pursuant to the Amended and Restated BRNI License, Neurotrope BioScience and BRNI entered into a new Statement of Work and Account Satisfaction Agreement dated February 4, 2015 (the “February 2015 SOW”). The February 2015 SOW is effective as of October 1, 2014 and continues until September 30, 2015. Neurotrope BioScience is obligated to pay $2.54 million pursuant to the February 2015 SOW (See Subsequent Events – Note 12). For the years ended December 31, 2014, Neurotrope BioScience incurred $600,000 in expenses relating to the February 2015 SOW, of which $400,000 was paid in 2014, and the remaining $200,000 was paid in 2015.
	Effective November 13, 2013, Neurotrope BioScience agreed to another SOW with in which Neurotrope BioScience contracted for the further development of its AD therapeutic product. Pursuant to this SOW, Neurotrope BioScience paid BRNI $251,939 for related personnel and research services. Neurotrope BioScience expensed this entire amount in the year ended December 31, 2013. No additional expense relating to this SOW was incurred during the year ended December 31, 2014.
	On March 12, 2014, Neurotrope BioScience signed an additional SOW with BRNI to continue pre-clinical activities relating to the commercialization of Neurotrope BioScience’s therapeutic product. Neurotrope BioScience paid BRNI the entire total pursuant to this SOW of approximately $465,000 for these services during the year ended December 31, 2014.

Income_Taxes

Income Taxes:	12 Months Ended
	Dec. 31, 2014
Income Tax Disclosure [Abstract]
Income Tax Disclosure [Text Block]	Note 7– Income Taxes:
	The Company incurred a net operating loss for income tax purposes of $13,685,763 for the period from October 31, 2012 (inception) through December 31, 2014. This amount is available for carryforward for use in offsetting taxable income of future years through 2034. The net operating loss carryforward resulted in a deferred tax asset of $4,653,159 at December 31, 2014. Income tax effects of share-based payments are recognized in the financial statements for those awards that will normally result in tax deductions under existing tax law. Under current U.S. federal tax law, the Company would receive a compensation expense deduction related to non-qualified stock options only when those options are exercised. Accordingly, the financial statement recognition of compensation cost for non-qualified stock options creates a deductible temporary difference which results in a deferred tax asset of $221,098 as of December 31, 2014. The Company does not recognize a tax benefit for compensation expense related to incentive stock options (ISOs) unless the underlying shares are disposed of in a disqualifying disposition. Accordingly, compensation expense related to ISOs is treated as a permanent difference for income tax purposes. These deferred tax assets are reduced to zero by an offsetting valuation allowance. As a result, there is no provision for income taxes.

Common_Stock

Common Stock:	12 Months Ended
	Dec. 31, 2014
STOCKHOLDERS' EQUITY [Abstract]
Stockholders Equity Note Disclosure [Text Block]	Note 8 – Common Stock:
	On February 28, 2013, Neurotrope BioScience amended and restated its Certificate of Incorporation to authorize 45,000,000 common shares at a par value of $0.01. On that date, the Company issued 19,000,000 common shares. This recapitalization has been presented retroactively in the accompanying financial statements.
	On June 20, 2013, BlueFlash Communications, Inc., a Florida corporation (“BlueFlash”), entered into an Agreement and Plan of Merger (the “Plan of Merger”) with Neurotrope, Inc., its wholly-owned Nevada subsidiary which was incorporated in Nevada on June 13, 2013, pursuant to which BlueFlash merged with and into Neurotrope, Inc. (the “Reincorporation Merger”). The Plan of Merger was amended by the Amendment to Agreement and Plan of Merger between the parties, dated July 10, 2013 (the “Amendment”). The purpose of the merger was to re-domicile BlueFlash from Florida to Nevada, and to effect a name change and recapitalization as described below.
	On August 5, 2013, Articles of Merger were filed with both the Secretary of State of the State of Nevada and the Secretary of State of the State of Florida, pursuant to which the Reincorporation Merger was effective as of August 9, 2013. Upon effectiveness of the merger, Neurotrope, Inc.’s Articles of Incorporation and Neurotrope, Inc.’s Amended and Restated Bylaws became the Articles of Incorporation and Amended and Restated Bylaws of the registrant.
	Neurotrope, Inc., has an authorized share capital of 300,000,000 shares of common stock, par value $0.0001 per share and 50,000,000 shares of “blank check” preferred stock, par value $0.0001 per share. Prior to the Reincorporation Merger, Neurotrope, Inc. had 100 shares of its common stock outstanding, held by BlueFlash, and therefore was a wholly-owned subsidiary of BlueFlash. Prior to the merger, Neurotrope, Inc. had no assets, liabilities or business.
	Pursuant to the Plan of Merger, among other things, each share of common stock of BlueFlash, $0.0001 par value per share was automatically converted into 2.242 shares of Neurotrope’s common stock.
	On August 23, 2013, the Reverse Merger occurred as described in Note 1 above, and all of the outstanding Neurotrope BioScience common stock was converted into shares of Neurotrope’s common stock on a one-for-one basis.
	In connection with the Reverse Merger and pursuant to a Split-Off Agreement, Neurotrope, Inc. transferred its pre-Reverse Merger business to Marissa Watson, its pre-Reverse Merger majority stockholder, in exchange for the surrender by her and cancellation of 20,178,000 shares of Neurotrope’s common stock.
	On September 25, 2014, the Company agreed to issue to a consultant 43,860 shares of common stock as compensation to assist the Company with investment banking and capital raising activities. The Company expensed $25,000 during the 2014 period as a general and administrative expense which represented the common stock issuable times the closing market price of the Company’s common stock on the date the consultant was engaged. During the year ended December 31, 2013, the Company issued (i) 9,600 shares of common stock to a consultant  as compensation for advisor services in connection with the Reverse Merger and (ii) 40,000 shares of common stock to a consultant for investor relations services, and as a result, incurred expenses totaling $44,640.
	During the year ended December 31, 2014, ten holders of 1,637,000 total shares of Preferred Stock converted that Preferred Stock into 1,637,000 shares of Neurotrope’s common stock and five holders of 613,228 warrants exercisable at $0.01 per share of common stock exercised their warrants into 613,228 shares of Neurotrope’s common stock.

Preferred_Stock

Preferred Stock:	12 Months Ended
	Dec. 31, 2014
Equity [Abstract]
Preferred Stock [Text Block]	Note 9 – Preferred Stock:
	Through a series of private placements closed between February and October 2013, Neurotrope BioScience issued 23,000,000 preferred shares at $1 per share, resulting in gross proceeds of $23 million. The Company agreed to pay the placement agent in the offering a cash commission of 10% of the gross funds raised from non-Company related investors in the private placement offering (“PPO”). As a result, the Company paid the placement agents cash totaling $2,225,000. In addition, the placement agent received (a) for the first $12,000,000 of gross PPO proceeds, (i) warrants exercisable for a period of ten (10) years to purchase a number of shares of common stock equal to 7.5% of the number of shares of Series A Preferred Stock sold to investors introduced by it, with a per share exercise price of $0.01, and (ii) warrants exercisable for a period of ten (10) years to purchase a number of shares of Series A Preferred Stock equal to 2.5% of the number of shares of Series A Preferred Stock sold to investors introduced by it, with a per share exercise price of $1.00; and (b) on gross PPO proceeds in excess of $12,000,000, warrants exercisable for a period of ten (10) years to purchase a number of shares of Series A Preferred Stock equal to 10% of the number of shares of Series A Preferred Stock sold to investors introduced by it, with an exercise price of $1.00 per share (collectively, the “Agent Warrants”). As a result of the foregoing aggregate placements, the placement agent was issued Agent Warrants to purchase 900,000 shares of the Company’s common stock and 1,325,000 shares of the Company’s Series A Preferred Stock.
	The Series A Preferred Stock ranks senior with respect to liquidation preference and dividend rights to the common stock and any other class or series of stock that the Company may issue. The Series A Preferred Stock accrues a dividend at an annual rate of $0.08 per share, when and if declared by the Board of Directors of the Company. No dividends have been declared on the Series A Preferred Stock. In the event of any voluntary or involuntary liquidation, dissolution or winding-up of our affairs or similar event, a holder of Series A Preferred Stock will be entitled to be paid, before any distribution or payment may be made to any holders of common stock or other class or series of stock, the liquidation amount (which shall equal $1.00 per share) and the amount of any accruable and unpaid dividends as of such distribution or payment date. Each share of Series A Preferred Stock is convertible into common stock at the option of the stockholder at a price of $1.00 per share, subject to adjustment. Each share of Series A Preferred Stock will convert into more than one share of common stock in the event that the Company sells certain securities at a price per share that is less than the conversion price, which is currently set at $1.00 per share. The Series A shares are subject to mandatory conversion upon the vote of holders of a majority of the outstanding shares of Series A Preferred Stock at any given time, or upon the closing of a sale of common stock to the public at a price of at least $5.00 per share (subject to adjustment in the case of certain events) in a firm commitment underwritten public offering pursuant to an effective registration statement under the Securities Act, resulting in net proceeds to the Company of at least $30,000,000. The holders of Series A Preferred Stock are entitled to a class vote on certain Company actions, have the right to participate in future offerings and have the right to elect one member of the Company board of directors, in addition to certain additional rights and privileges as set forth in the Amended and Restated Certificate of Incorporation and in certain agreements between the Company and the holders thereof.
	As of September 2, 2014, the Company and the holders of a majority of the Company’s Series A Preferred Stock entered into an amendment (the “Amendment”) to the Preferred Stockholders Agreement, dated as of August 23, 2013 (the “Preferred Stockholder Agreement”). Under the terms of the Amendment, the parties removed provisions relating to the right of first refusal and certain prohibitions relating to transfers, which were set forth in the Preferred Stockholder Agreement. In addition, the parties made other technical changes to the terms of the Preferred Stockholder Agreement.
	During 2014, private placement investors converted a total of 1,637,000 shares of the Company’s Series A Preferred Stock into 1,637,000 shares of the Company’s common stock.

Stock_Options

Stock Options:	12 Months Ended
	Dec. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award, Additional General Disclosures [Abstract]
Stock Option Note Disclosure [Text Block]	Note 10 – Stock Options:
	Our Board of Directors adopted, and our stockholders approved, the 2013 Plan, which provides for the issuance of incentive awards of up to 7,000,000 shares of the Company’s common stock to officers, key employees, consultants and directors. Upon the closing of the Reverse Merger, options to purchase an aggregate of 5,154,404 shares of the Company’s common stock were issued. Of these options: (a) 3,500,000 options were issued to founding stockholders and 54,404 were granted to a consultant, each with a term of ten years, exercisable at $1.75 per common share, 100% of these options vested on the date of grant; (b) 1,050,000 options were issued to four directors (or their affiliates) and 250,000 to a consultant with a term of ten years, exercisable at $1.00 per common share, which vest 20% per year for each of five years after the date of grant; and, (c) 300,000 options were granted to a consultant with a term of ten years, exercisable at $1.00 per common share which vested 20% on the date of grant and vest 20% per year over the next four years. These options were issued in conversion of options issued by Neurotrope BioScience on February 28, 2013.
	On January 23, 2014, the Company issued, under the 2013 Plan, 300,000 options to three employees, each with a term of ten years, exercisable at $1.76 per common share. 125,000 of these options vest 25% per year, with accelerated vesting of 25% upon a termination without cause or for good reason, with the remaining 175,000 vesting 20% per year. On March 21, 2014, the Company issued, under the 2013 Plan, 30,000 options to one employee with a term of ten years, exercisable at $2.30 per common share and vests 20% per year commencing on March 31, 2015.
	On July 16, 2014, the Company issued incentive stock options to purchase 50,000 shares of common stock under the 2013 Plan to one employee with a term of ten years, exercisable at $1.24 per common share which vest 20% per year commencing July 16, 2015.
	On July 23, 2014, the Company’s Board approved increasing the total shares available under the 2013 Plan by 3,000,000 to 10,000,000. The 3,000,000 additional shares will be issuable as non-qualified stock options, unless shareholder approval is sought and received.
	Also, on July 23, 2014, the Board granted non-qualified stock options to three directors, each in the amount of 100,000 shares of common stock; 50,000 of which have an exercise price equal to $1.11, being ten cents ($0.10) above the closing sales price of the common stock (or the closing bid, if no sales were reported) as listed on the OTC Market on July 23, 2014, which vested on the date of the grant hereof; and 50,000 of which have an exercise price equal to two times the value of the exercise price of the first 50,000 options, or $2.22 which vest daily over four (4) years (assuming continued service on behalf of the Company), up to 25% per year, such that 25% of the second 50,000 shall be vested on July 23, 2015 until the grant is fully vested on July 23, 2018.
	On September 12, 2014, the Board granted the Company’s Chief Executive Officer and Chairman non-qualified options to purchase 250,000 and 50,000 shares of the Company’s common stock, respectively, which have an exercise price of $0.60 per common share, are fully vested upon grant and have a term of ten years. Also, the Board granted 300,000 non-qualified stock options to a newly appointed director with a term of ten years, exercisable at $0.60 per common share and vest daily over five years commencing September 12, 2014. The Company also granted incentive stock options to purchase 20,000 shares of the Company’s common stock to one employee with a term of ten years, exercisable at $0.60 per common share and vests 20% per year commencing September 12, 2015.
	A summary of the Company’s stock option activity for the years ended December 31, 2014 and 2013 is as follows:
		Options	Weighted-Average
		Outstanding	Exercise Price
	Outstanding at January 1, 2013	0	$	0
	Options granted	6,489,404	$	1.47
	Options granted	-239,452	$	-1
	Options exercised	0		0
	Outstanding at December 31, 2014	6,249,952	$	1.48
	Options exercisable December 31, 2013	3,764,733	$	1.71
	Outstanding at December 31, 2013	6,249,952	$	1.48
	Options granted	2,350,000	$	1.29
	Options granted	-830,750	$	1.77
	Options exercised	0		0
	Outstanding at December 31, 2014	7,769,202	$	1.4
	Options exercisable December 31, 2014	4,546,603	$	1.49
	The weighted-average remaining contractual term of options exercisable and outstanding at December 31, 2014 was approximately 8.5 and 8.9 years, respectively.
	The Company used the Black-Scholes valuation model to calculate the fair value of stock options. Stock-based compensation expense is recognized over the vesting period using the straight-line method.
	The fair value of stock options issued for the year ended December 31, 2014 was estimated at the grant date using the following weighted average assumptions: Dividend yield 0%; Volatility 90.56%; Risk-free interest rate 2.53%; weighted average grant date fair value of $0.77 per common share.
	The total stock option-based compensation recorded as operating expense was approximately $1,203,000 and $3,123,000 for the years ended December 31, 2014 and 2013, respectively. All of the stock option-based compensation expense was classified as stock based compensation expense.

Common_and_Preferred_Stock_Res

Common and Preferred Stock Reserved for Future Issuances:	12 Months Ended
	Dec. 31, 2014
Common And Preferred Stock Reserved For Future Issuances [Abstract]
Common And Preferred Stock Reserved For Future Issuances [Text Block]	Note 11 – Common and Preferred Stock Reserved for Future Issuances:
	Common stock and preferred stock reserved for future issuances consisted of the following at December 31, 2014:
		Common Stock		Preferred Stock
		Reserved		Reserved
	Common stock warrants outstanding		286,772		0
	Preferred stock warrants outstanding		1,325,000		1,325,000
	Common stock options outstanding		7,769,202		0
	Conversion of Series A Preferred Stock		21,363,000		0
	Total		30,743,974		1,325,000
	On February 9, 2015, the holders of the Preferred stock warrants outstanding agreed to convert these warrants to Common stock warrants with the same terms as the Preferred stock warrants (See Subsequent Events – Note 12)

Subsequent_Events

Subsequent Events:	12 Months Ended
	Dec. 31, 2014
Subsequent Events [Abstract]
Subsequent Events [Text Block]	Note 12 – Subsequent Events:
	From January 1 through March 20, 2015, private placement investors converted a total of 2,580,606 shares of the Company’s Series A Preferred Stock (issued in 2013) into 2,580,606 shares of the Company’s common stock.
	Additionally, from January 1 through March 26, 2015, private placement investors exercised common stock warrants (issued August 23, 2013) resulting in the issuance of a total of  180,558 shares of the Company’s common stock.
	On February 9, 2015, the holders of placement agent warrants to purchase an aggregate of 1,325,000 shares of our Series A Preferred Stock entered into Conversion Agreements with us pursuant to which such holders’ placement agent warrants to purchase Series A Preferred Stock were converted, for no additional consideration, into common stock purchase warrants to purchase an aggregate of 1,325,000 shares of our common stock.
	On February 4, 2015, Neurotrope BioScience entered into an Amended and Restated Technology License and Services Agreement with BRNI and NRV II, LLC. The agreement further amended and restated that certain Technology License and Services Agreement executed as of October 31, 2012, which was previously amended by Amendment No. 1 to the Technology License and Services Agreement as of August 21, 2013.
	Pursuant to the Amended and Restated BRNI License, on February 4, 2015, Neurotrope BioScience and BRNI entered into a new Statement of Work and Account Satisfaction Agreement, or the February 2015 SOW, pursuant to the BRNI License. The February 2015 SOW is effective as of October 1, 2014 and continues until September 30, 2015.
	The February 2015 SOW terminates and replaces the SOW dated August 28, 2013 and both parties agreed that neither party has or shall have any rights, claims damages or obligations for services or costs pursuant to the August 28, 2013 SOW.
	Pursuant to the February 2015 SOW, Neurotrope BioScience agreed to pay BRNI two million four hundred thousand dollars ($2,400,000) in service fees and other amounts payable at a rate of two hundred thousand dollars ($200,000) per month for each month from October 1, 2014 through September 30, 2015. The parties agreed that the first six hundred thousand dollars ($600,000) of payments satisfy certain outstanding amounts owed to BRNI. Of this $600,000, $400,000 was paid in 2014, and the remaining $200,000 was paid in 2015. Neurotrope BioScience also agreed to pay BRNI twenty thousand dollars ($20,000) in quarterly payments during the twelve months from the date of the SOW in exchange for advising and consulting services by BRNI’s chief scientist regarding Neurotrope BioScience’s contract with the Icahn School of Medicine at Mt. Sinai Hospital for the use of bryostatin in the treatment of Niemann Pick disease.
	In consideration for the February 2015 SOW, BRNI agrees to (a) use commercially reasonable efforts to enroll at least four (4) additional compassionate use or expanded access patients, in trials of BRNI’s Alzheimer’s therapeutic drug platform during the term of the SOW, (b) perform certain services requested by Neurotrope BioScience for the further development of BRNI’s Alzheimer’s therapeutic drug platform, (c) perform certain services for the further development of BRNI’s Alzheimer’s diagnostic test, (d) to the extent permitted by applicable law, transfer all of its rights and regulatory obligations, except for those relating to the compassionate use expanded access trials, associated with BRNI’s IND 71,276 to Neurotrope BioScience, (e) conduct initial research on the application of its PKC epsilon platform to treat Fragile X disease, (f) conduct initial research on polyunsaturated fatty acid derivatives for the purpose of developing a commercially usable PKC epsilon activator, and (g) provide assistance, advice and other similar services to Neurotrope BioScience regarding Neurotrope BioScience’s analysis of bryologs pursuant to Neurotrope BioScience’s agreement with Stanford University, for the purpose of developing a commercially usable PKC epsilon activator. Furthermore, BRNI agreed to transfer a certain amount of bryostatin drug substance and bryostatin kits containing drug substance for non-human use to a third-party for storage and handling for Neurotrope BioScience’s pre-clinical and clinical use, which was completed on March 10, 2015.
	In order for BRNI to perform certain of the services described in (c) above, Neurotrope BioScience agrees to reimburse a third party for services BRNI received from such third party in the amount of one hundred fifty thousand dollars ($150,000) in connection with BRNI’s former diagnostic trial program with such third party. Also, under certain conditions, Neurotrope BioScience has agreed to enter into an agreement with a specified research institution for the analysis of tissue samples and autopsy results for a validation trial as part of the development process for the diagnostic test. If Neurotrope BioScience does not proceed with a certain portion of such agreement by June 30, 2015, then the rights to the diagnostic test will revert to BRNI and Neurotrope BioScience will no longer be licensed thereto.

Summary_of_Significant_Account1

Summary of Significant Accounting Policies: (Policies)	12 Months Ended
	Dec. 31, 2014
SUMMARY OF SIGNIFICANT ACCOUNTING PRACTICES [Abstract]
New Accounting Pronouncements, Policy [Policy Text Block]	Recently Adopted Accounting Standards:
	In June 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update No. 2014-10, Development Stage Entities (Topic 915) – Elimination of Certain Financial Reporting Requirements, Including an Amendment to Variable Interest Entities Guidance in Topic 810, Consolidation (“ASU 2014-10”). ASU 2014-10 eliminates the concept of a development stage entity in its entirety from current accounting guidance. The new guidance eliminates the requirements for development stage entities to (i) present inception-to-date information in the statement of operations, stockholders’ equity and cash flows, (ii) label the financial statements as those of a development stage entity, (iii) disclose a description of the development stage activities in which the entity is engaged, and (iv) disclose in the first year in which the entity is no longer a development stage entity that in prior years it had been in the development stage. ASU 2014-10 is effective prospectively for public entities for annual reporting periods beginning after December 15, 2015, and interim periods within those annual periods; however, early adoption is permitted. The Company elected to adopt ASU 2014-10 as permitted, for the financial statements ended December 31, 2014 and, accordingly, has not included the inception-to-date disclosures and other previously required disclosures for development stage entities.
Use of Estimates, Policy [Policy Text Block]	Use of Estimates:
	The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
Reclassification, Policy [Policy Text Block]	Reclassifications:
	Certain reclassifications have been made to the 2013 financial statements to conform to the consolidated 2014 financial statement presentation. These reclassifications had no effect on net loss or cash flows as previously reported.
Cash and Cash Equivalents, Policy [Policy Text Block]	Cash and Cash Equivalents:
	The Company considers all highly liquid temporary cash investments with an original maturity of three months or less when purchased to be cash equivalents. At December 31, 2014, the Company’s cash balances may exceed the current insured amounts under the Federal Deposit Insurance Corporation.
Property, Plant and Equipment, Policy [Policy Text Block]	Property and Equipment:
	Property and equipment is capitalized and depreciated on a straight line basis over the useful life of the asset, which is deemed to be between three and ten years. Property and equipment consist of the following at December 31:
		2014		2013
	Property and equipment	$	54,943	$	0
	Accumulated depreciation	$	-1,325	$	0
	Property and equipment, net	$	53,618	$	0
	Depreciation expense for the year ended December 31, 2014 was $1,325 compared to $0 for 2013.
Research and Development Expense, Policy [Policy Text Block]	Research and Development Costs:
	All research and development costs, including costs to maintain or expand the Company’s patent portfolio that do not meet the criteria for capitalization are expensed when incurred. FASB ASC Topic 730 requires companies involved in research and development activities to capitalize non-refundable advance payments for such services pursuant to contractual arrangements because the right to receive those services represents an economic benefit. Such capitalized advances will be expensed when the services occur and the economic benefit is realized. There were no capitalized research and development services at December 31, 2014 and 2013.
Income Tax, Policy [Policy Text Block]	Income Taxes:
	Income taxes are provided for the tax effects of transactions reported in the financial statements and consist of taxes currently due and deferred taxes. Deferred taxes are recognized for differences between the bases of assets and liabilities for financial statement and income tax purposes and the tax effects of net operating loss and other carryforwards. The deferred tax assets and liabilities represent the future tax consequences of those differences and carryforwards, which will either be taxable or deductible when the related assets, liabilities or carryforwards are recovered or settled. Deferred tax assets are reduced by a valuation allowance when, based on the weight of available evidence, it is more likely than not that some portion or all of the deferred tax assets will not be realized.
	The Company applies the provisions of FASB ASC 740-10, Accounting for Uncertain Tax Positions, which clarifies the accounting for uncertainty in income taxes recognized in an enterprise’s financial statements and prescribes a recognition threshold and measurement process for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. The standard also provides guidance on de-recognition, classification, interest and penalties, and accounting in interim periods, disclosure and transitions.
	The Company has concluded that there are no significant uncertain tax positions requiring recognition in the accompanying financial statements. The tax period that is subject to examination by major tax jurisdictions is from October 31, 2012 (inception) through December 31, 2014.
	In the event the Company was to receive an assessment for interest and/or penalties, it will be classified in the financial statements as selling, general and administrative expense when assessed.
Concentration Risk, Credit Risk, Policy [Policy Text Block]	Risks and Uncertainties:
	The Company operates in an industry that is subject to rapid technological change, intense competition and significant government regulation. The Company’s operations are subject to significant risk and uncertainties including financial, operational, technological, regulatory and other risk. Such factors include, but are not necessarily limited to, the results of clinical testing and trial activities, the ability to obtain regulatory approval, the ability to obtain favorable licensing, manufacturing or other agreements for its product candidates and the ability to raise capital to achieve strategic objectives.
Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]	Stock Compensation:
	The Company accounts for stock-based awards to employees in accordance with applicable accounting principles, which requires compensation expense related to share-based transactions, including employee stock options, to be measured and recognized in the financial statements based on a determination of the fair value of the stock options. The grant date fair value is determined using the Black-Scholes-Merton (“Black-Scholes”) pricing model. For all employee stock options, we recognize expense over the employee’s requisite service period (generally the vesting period of the equity grant). The Company’s option pricing model requires the input of highly subjective assumptions, including the expected stock price volatility, expected term, and forfeiture rate. Any changes in these highly subjective assumptions significantly impact stock-based compensation expense.
	Options awarded to purchase shares of common stock issued to non-employees in exchange for services are accounted for as variable awards in accordance with applicable accounting principles. Such options are valued using the Black-Scholes option pricing model.

Summary_of_Significant_Account2

Summary of Significant Accounting Policies: (Tables)	12 Months Ended
	Dec. 31, 2014
SUMMARY OF SIGNIFICANT ACCOUNTING PRACTICES [Abstract]
Property, Plant and Equipment [Table Text Block]	Property and equipment is capitalized and depreciated on a straight line basis over the useful life of the asset, which is deemed to be between three and ten years. Property and equipment consist of the following at December 31:
		2014		2013
	Property and equipment	$	54,943	$	0
	Accumulated depreciation	$	-1,325	$	0
	Property and equipment, net	$	53,618	$	0

Stock_Options_Tables

Stock Options: (Tables)	12 Months Ended
	Dec. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award, Additional General Disclosures [Abstract]
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]	A summary of the Company’s stock option activity for the years ended December 31, 2014 and 2013 is as follows:
		Options	Weighted-Average
		Outstanding	Exercise Price
	Outstanding at January 1, 2013	0	$	0
	Options granted	6,489,404	$	1.47
	Options granted	-239,452	$	-1
	Options exercised	0		0
	Outstanding at December 31, 2014	6,249,952	$	1.48
	Options exercisable December 31, 2013	3,764,733	$	1.71
	Outstanding at December 31, 2013	6,249,952	$	1.48
	Options granted	2,350,000	$	1.29
	Options granted	-830,750	$	1.77
	Options exercised	0		0
	Outstanding at December 31, 2014	7,769,202	$	1.4
	Options exercisable December 31, 2014	4,546,603	$	1.49

Common_and_Preferred_Stock_Res1

Common and Preferred Stock Reserved for Future Issuances: (Tables)	12 Months Ended
	Dec. 31, 2014
Common And Preferred Stock Reserved For Future Issuances [Abstract]
Schedule of Guarantor Obligations [Table Text Block]	Common stock and preferred stock reserved for future issuances consisted of the following at December 31, 2014:
		Common Stock		Preferred Stock
		Reserved		Reserved
	Common stock warrants outstanding		286,772		0
	Preferred stock warrants outstanding		1,325,000		1,325,000
	Common stock options outstanding		7,769,202		0
	Conversion of Series A Preferred Stock		21,363,000		0
	Total		30,743,974		1,325,000

Summary_of_Significant_Account3

Summary of Significant Accounting Policies: (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Property, Plant and Equipment [Line Items]
Property and equipment	$54,943	$0
Accumulated depreciation	-1,325	0
Property and equipment, net	$53,618	$0

Summary_of_Significant_Account4

Summary of Significant Accounting Policies: (Details Textual) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Summary Of Significant Accounting Policies [Line Items]
Depreciation, Depletion and Amortization	$1,325	$0
Maximum [Member]
Summary Of Significant Accounting Policies [Line Items]
Property, Plant and Equipment, Useful Life	10 years
Minimum [Member]
Summary Of Significant Accounting Policies [Line Items]
Property, Plant and Equipment, Useful Life	3 years

Contractual_Commitments_Detail

Contractual Commitments: (Details Textual) (USD $)

0 Months Ended

2 Months Ended

12 Months Ended

0 Months Ended

1 Months Ended

0 Months Ended

1 Months Ended

0 Months Ended

Sep. 04, 2014

Feb. 28, 2013

Dec. 31, 2014

Dec. 31, 2013

Sep. 12, 2014

Jul. 16, 2014

Feb. 28, 2013

Jul. 23, 2014

Jun. 30, 2014

Jan. 31, 2014

Oct. 30, 2013

Nov. 01, 2014

Feb. 25, 2013

Oct. 09, 2014

sqft

Contractual Commitments And Contingencies [Line Items]

General Contractor Costs

$20,833

Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term

8 years 6 months

Area of Land

4,000

Description of Lessor Leasing Arrangements, Operating Leases

The lease commenced September 1, 2014 and expires December 1, 2017 and has two (2) one-year renewal options.

Accrued Rent

88,000

Operating Leases, Rent Expense

28,927

Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price

$1.29

$1.47

Ramat [Member]

Contractual Commitments And Contingencies [Line Items]

Consulting Fees

400,000

20,000

50,000

Service Cost Paid Under Installment

4,167

Stock Option Entitled To Related Party

300,000

Stock Option Entitled To Related Party Purchase Price Per Share

$1

$1

Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage

20.00%

Targeted Bonus Percentage Of Base Consulting Fees

50.00%

Consulting Fees Total

50,000

Freiman [Member]

Contractual Commitments And Contingencies [Line Items]

Consulting Fees

20,000

Freiman And Ramat [Member]

Contractual Commitments And Contingencies [Line Items]

Consulting Fees

20,000

Consulting Fees Reduced Amount

10,000

Share-based Compensation Arrangement by Share-based Payment Award, Description

options to purchase 400,000 shares of the Companys common stock for their roles as directors, Co-Chairmen of the Board and Co-Chief Executive Officers. Options to purchase 200,000 shares have an exercise price of $1.11 per share, or 110% of the Companys last trading price on July 23, 2014 and were fully vested upon grant. Options to purchase the remaining 200,000 shares have an exercise price of $2.22 per share based upon two times the exercise price of $1.11 per share and vest on a daily basis up to 25% per year through July 23, 2018

Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price

$0.60

Executive Director - Pharmacology [Member]

Contractual Commitments And Contingencies [Line Items]

Annual Salary Providing Under Agreement

180,000

Targeted Bonus Percentage Of Base Salary

25.00%

Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period

50,000

Employment Contracts [Member] | Vice President - Commercial Operations [Member]

Contractual Commitments And Contingencies [Line Items]

Annual Salary Providing Under Agreement

210,000

Targeted Bonus Percentage Of Base Salary

35.00%

Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term

10 years

Employment Contracts [Member] | Chief Medical Officer and Vice President [Member]

Contractual Commitments And Contingencies [Line Items]

Annual Salary Providing Under Agreement

210,000

Targeted Bonus Percentage Of Base Salary

35.00%

Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term

10 years

Employment Contracts [Member] | Chief Financial Officer [Member]

Contractual Commitments And Contingencies [Line Items]

Annual Salary Providing Under Agreement

240,000

Increasing Decrease In Annual Salary

275,000

Bonus

50,000

35,000

Employment Contracts [Member] | Chief Financial Officer [Member] | Scenario, Forecast [Member]

Contractual Commitments And Contingencies [Line Items]

Targeted Bonus Percentage Of Base Salary

50.00%

Employment Contracts [Member] | Executive Vice President [Member]

Contractual Commitments And Contingencies [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage

20.00%

Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period

5 years

Salaries, Wages and Officers' Compensation

325,000

Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized

250,000

Deferred Compensation Arrangement with Individual, Exercise Price

$0.71

Deferred Compensation Arrangement with Individual, Maximum Contractual Term

1 year

Employment Contracts [Member] | Executive Vice President [Member] | Deferred Bonus [Member]

Contractual Commitments And Contingencies [Line Items]

Monthly Signing Bonus

8,507

Salaries, Wages and Officers' Compensation

102,083

Deferred Compensation Arrangement with Individual, Cash Awards Granted, Percentage

50.00%

Employment Contracts [Member] | Qualifed Stock Option [Member] | Vice President - Commercial Operations [Member]

Contractual Commitments And Contingencies [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period

5 years

Share Based Compensation Arrangement By Share Based Payment Award Options Vested Percentage

20.00%

Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period

100,000

Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price

$1.76

Employment Contracts [Member] | Qualifed Stock Option [Member] | Chief Medical Officer and Vice President [Member]

Contractual Commitments And Contingencies [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage

25.00%

Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period

4 years

Share Based Compensation Arrangement By Share Based Payment Award Options Vested Percentage

25.00%

Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period

31,250

125,000

Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price

$1.76

Severance Costs

217,000

Employment Contracts [Member] | Qualifed Stock Option [Member] | Chief Financial Officer [Member]

Contractual Commitments And Contingencies [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage

25.00%

Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period

4 years

Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period

650,000

Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term

10 years

Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price

$1

Non-Qualified Stock Options [Member] | Ramat [Member]

Contractual Commitments And Contingencies [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period

250,000

Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term

10 years

Non-Qualified Stock Options [Member] | Freiman [Member]

Contractual Commitments And Contingencies [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period

50,000

Independent Contractor Agreement [Member]

Contractual Commitments And Contingencies [Line Items]

Annual Salary Providing Under Agreement

250,000

Annual Bonus Providing Under Agreement

50,000

Increasing Decrease In Annual Salary

300,000

Increasing Decrease In Annual bonus

100,000

Separation Agreement [Member] | Former President [Member]

Contractual Commitments And Contingencies [Line Items]

Reimbursement Of Attorney Fee

17,000

Deferred Compensation Arrangement with Individual, Compensation Expense

2,684

Deferred Compensation Arrangement with Individual, Cash Award Granted, Amount

233,000

Accrued Vacation

25,478

Supplemental Unemployment Benefits, Continuation of Health Care

2,974

Deferred Compensation Arrangement with Individual, Distributions Paid

$282,000

Series A Preferred Stock [Member] | Ramat [Member]

Contractual Commitments And Contingencies [Line Items]

Stock Option Entitled To Related Party

1,000,000

Collaborative_Agreements_Detai

Collaborative Agreements: (Details Textual) (USD $)	12 Months Ended
	Dec. 31, 2014
Contract Research Organization [Member]
Collaborative Agreements [Line Items]
Commitment To Pay Fees	$715,159
Accounts payable and accrued expenses	417,877
Reduction Of Commitment Fees	657,238
Stanford Agreement [Member]
Collaborative Agreements [Line Items]
License Initiation Fee	60,850
Annual License Maintenance Fee	10,000
Milestone Payments Upon Achievement Of Certain Product	3,700,000
Payment For License Agreement Fees	48,564
Mount Sinai Agreement [Member]
Collaborative Agreements [Line Items]
License Initiation Fee	25,000
Annual License Maintenance Fee	10,000
Milestone Payments Upon Achievement Of Certain Product	3,500,000
Accounts payable and accrued expenses	12,000
Payment For License Agreement Fees	$11,458

Related_Party_Transactions_and1

Related Party Transactions and Licensing / Research Agreements: (Details Textual) (USD $)	1 Months Ended	12 Months Ended		0 Months Ended	1 Months Ended		3 Months Ended	1 Months Ended
	Feb. 28, 2013	Dec. 31, 2014	Dec. 31, 2013	Nov. 13, 2013	Feb. 28, 2015	Mar. 31, 2013	Mar. 31, 2015	Aug. 31, 2013	Jul. 31, 2013	Oct. 04, 2013
Related Party Transaction [Line Items]
Technology Services Costs	$266,666
Research and Development Expense, Total		1,242,706	0
Blanchette Rockefeller Neurosciences Institute [Member]
Related Party Transaction [Line Items]
Research and Development Expense, Total				251,939
Scenario, Forecast [Member]
Related Party Transaction [Line Items]
Research and Development Expense, Total		1,000,000
Subsequent Event [Member]
Related Party Transaction [Line Items]
Technology Services Costs					600,000
Fixed Research Fee [Member]
Related Party Transaction [Line Items]
Research and Development Expense, Total		1,000,000
Services Reimbursement [Member]
Related Party Transaction [Line Items]
Royalties Percentage		5.00%
Royalty Expense						409,549
Services Reimbursement [Member] | Minimum [Member]
Related Party Transaction [Line Items]
Royalties Percentage		2.00%
Services Reimbursement [Member] | Maximum [Member]
Related Party Transaction [Line Items]
Royalties Percentage		5.00%
Statement Of Work Agreement [Member]
Related Party Transaction [Line Items]
Payments to Acquire Productive Assets, Total		1,645,470
Payment to Be Paid Upon Completion		465,000
Payments for Fees		400,000
Statement Of Work Agreement [Member] | Subsequent Event [Member]
Related Party Transaction [Line Items]
Due to Other Related Parties					2,540,000
Payments for Fees							200,000
Statement Of Work Agreement [Member] | Monthly Installment [Member]
Related Party Transaction [Line Items]
Payments to Acquire Productive Assets, Total		137,123
Series A Preferred Stock [Member]
Related Party Transaction [Line Items]
Prepaid Royalties										48,600
Series A Preferred Stock [Member] | Technology License And Services Agreement [Member]
Related Party Transaction [Line Items]
Proceeds from Issuance of Preferred Stock and Preference Stock	8,000,000
Series A Preferred Stock [Member] | Services Reimbursement [Member]
Related Party Transaction [Line Items]
Royalty Expense									60,349
Royalty Prepaid								520,252
Series B Preferred Stock [Member] | Fixed Research Fee [Member]
Related Party Transaction [Line Items]
Proceeds from Issuance of Preferred Stock and Preference Stock		$25,000,000
Director [Member]
Related Party Transaction [Line Items]
Equity Method Investment, Ownership Percentage		37.60%

Income_Taxes_Details_Textual

Income Taxes: (Details Textual) (USD $)	26 Months Ended
	Dec. 31, 2014
Income Tax Expenses Benefit [Line Items]
Operating Income (Loss)	$13,685,763
Deferred Tax Assets, Gross, Current	4,653,159
Deferred Tax Assets, Net	$221,098

Common_Stock_Details_Textual

Common Stock: (Details Textual) (USD $)	0 Months Ended	12 Months Ended	0 Months Ended	12 Months Ended
	Aug. 23, 2013	Dec. 31, 2014	Sep. 25, 2014	Dec. 31, 2013	Feb. 28, 2013
Class of Stock [Line Items]
Common Stock, Shares Authorized		300,000,000		300,000,000
Common Stock, Par or Stated Value Per Share		$0.00		$0.00
Common Stock, Shares, Issued		24,034,094		21,740,006
Common Stock, Shares, Outstanding		24,034,094		21,740,006
Conversion of Stock, Shares Converted		1,637,000
Common Stock, Conversion Basis	one-for-one basis
Convertible Preferred Stock, Shares Issued upon Conversion		1,637,000
General and Administrative Expense [Member]
Class of Stock [Line Items]
Payments of Stock Issuance Costs		$25,000
Consultant [Member]
Class of Stock [Line Items]
Stock Issued During Period, Shares, Issued for Services				9,600
Share-based Goods and Nonemployee Services Transaction, Shares Approved for Issuance			43,860
Payments of Stock Issuance Costs				$44,640
Investor relations services [Member]
Class of Stock [Line Items]
Stock Issued During Period, Shares, Issued for Services				40,000
Series A Preferred Stock [Member]
Class of Stock [Line Items]
Conversion of Stock, Shares Converted		1,637,000
Convertible Preferred Stock, Shares Issued upon Conversion		1,637,000
Blue Flash Common Stock [Member]
Class of Stock [Line Items]
Common Stock, Shares, Outstanding		100
Common Stock [Member]
Class of Stock [Line Items]
Stock Issued During Period, Shares, Issued for Services		43,860		49,600
Blank Check [Member]
Class of Stock [Line Items]
Preferred Stock, Shares Authorized		50,000,000
Preferred Stock, Par or Stated Value Per Share		$0.00
Neurotrope Inc. [Member]
Class of Stock [Line Items]
Surrender Of Share		20,178,000
Neurotrope Inc. [Member] | Common Stock [Member]
Class of Stock [Line Items]
Warrants Exercisable		613,228
Class of Warrant or Right, Number of Securities Called by Warrants or Rights		613,228
Class of Warrant or Right, Exercise Price of Warrants or Rights		$0.01
NBI [Member]
Class of Stock [Line Items]
Common Stock, Shares Authorized					45,000,000
Common Stock, Par or Stated Value Per Share					$0.01
Common Stock, Shares, Issued					19,000,000
Blue Flash [Member]
Class of Stock [Line Items]
Business Acquisition, Equity Interest Issued or Issuable, Description		each share of common stock of BlueFlash, $0.0001 par value per share was automatically converted into 2.242 shares of Neurotropes common stock.

Preferred_Stock_Details_Textua

Preferred Stock: (Details Textual) (USD $)	12 Months Ended
	Dec. 31, 2014	Oct. 31, 2013	Feb. 28, 2013
Class of Stock [Line Items]
Payment To Private Placement Agent Description	The Company agreed to pay the placement agent in the offering a cash commission of 10% of the gross funds raised from non-Company related investors in the private placement offering (“PPO”).
Warrants issued to placement agent description	(a) for the first $12,000,000 of gross PPO proceeds, (i) warrants exercisable for a period of ten (10) years to purchase a number of shares of common stock equal to 7.5% of the number of shares of Series A Preferred Stock sold to investors introduced by it, with a per share exercise price of $0.01, and (ii) warrants exercisable for a period of ten (10) years to purchase a number of shares of Series A Preferred Stock equal to 2.5% of the number of shares of Series A Preferred Stock sold to investors introduced by it, with a per share exercise price of $1.00; and (b) on gross PPO proceeds in excess of $12,000,000, warrants exercisable for a period of ten (10) years to purchase a number of shares of Series A Preferred Stock equal to 10% of the number of shares of Series A Preferred Stock sold to investors introduced by it, with an exercise price of $1.00 per share (collectively, the “Agent Warrants”). As a result of the foregoing aggregate placements, the placement agent was issued Agent Warrants to purchase 900,000 shares of the Company’s common stock and 1,325,000 shares of the Company’s Series A Preferred Stock.
Conversion of Stock, Shares Converted	1,637,000
Convertible Preferred Stock, Shares Issued upon Conversion	1,637,000
Private Placement [Member] | NBI [Member]
Class of Stock [Line Items]
Preferred Stock, Shares Issued		23,000,000
Preferred Stock, Par or Stated Value Per Share	$1		$1
Preferred Stock, Value, Issued		$23,000,000
Payment To Placement Agents	2,225,000
Series A Preferred Stock [Member]
Class of Stock [Line Items]
Preferred Stock, Dividend Rate, Per-Dollar-Amount	$0.08
Sale of Stock, Price Per Share	$5
Conversion of Stock, Amount Issued	$30,000,000
Preferred Stock, Liquidation Preference Per Share	$1
Conversion of Stock, Shares Converted	1,637,000
Convertible Preferred Stock, Shares Issued upon Conversion	1,637,000

Stock_Options_Details

Stock Options: (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Outstanding	6,249,952	0
Options granted	2,350,000	6,489,404
Options terminated	-830,750	-239,452
Options exercised	0	0
Outstanding	7,769,202	6,249,952
Options exercisable	4,546,603	3,764,733
Weighted-Average Exercise Price, Outstanding	$1.48	$0
Weighted-Average Exercise Price, Options granted	$1.29	$1.47
Weighted - Average Exercise Price, Options terminated	$1.77	($1)
Weighted-Average Exercise Price, Options exercised	$0	$0
Weighted-Average Exercise Price, Outstanding	$1.40	$1.48
Weighted-Average Exercise Price, Options exercisable	$1.49	$1.71

Stock_Options_Details_Textual

Stock Options: (Details Textual) (USD $)	12 Months Ended		1 Months Ended	0 Months Ended	1 Months Ended		0 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Jul. 23, 2014	Sep. 12, 2014	Jan. 23, 2014	Mar. 21, 2014	Jul. 16, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price	$1.49	$1.71
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate	0.00%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate	90.56%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate	2.53%
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value	$0.77
Share-based Compensation, Total	$950,795	$268,199
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term	8 years 6 months
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term		8 years 10 months 24 days
Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation, Total	$1,203,000	$3,123,000
Non-Qualified Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period			3,000,000
Director [Member] | Non-Qualified Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period				300,000
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period				10 years
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price				$0.60
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period				5 years
Three Employee [Member] | Plan 2013 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period					300,000
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period					10 years
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price					$1.76
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights					125,000 of these options vest 25% per year, with accelerated vesting of 25% upon a termination without cause or for good reason, with the remaining 175,000 vesting 20% per year.
One Employee [Member] | Plan 2013 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period						30,000
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period						10 years
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price						$2.30
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage						20.00%
Chief Executive Officer [Member] | Non-Qualified Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period				250,000
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period				10 years
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price				$0.60
Chairman [Member] | Non-Qualified Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period				50,000
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period				10 years
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price				$0.60
Equity Incentive Plan 2013 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized	7,000,000
Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period	5,154,404
Share-based Compensation Arrangement by Share-based Payment Award, Description			Also, on July 23, 2014, the Board granted non-qualified stock options to three directors, each in the amount of 100,000 shares of common stock; 50,000 of which have an exercise price equal to $1.11, being ten cents ($0.10) above the closing sales price of the common stock (or the closing bid, if no sales were reported) as listed on the OTC Market on July 23, 2014, which vested on the date of the grant hereof; and 50,000 of which have an exercise price equal to two times the value of the exercise price of the first 50,000 options, or $2.22 which vest daily over four (4) years (assuming continued service on behalf of the Company), up to 25% per year, such that 25% of the second 50,000 shall be vested on July 23, 2015 until the grant is fully vested on July 23, 2018.
Equity Incentive Plan 2013 [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period			10,000,000
Equity Incentive Plan 2013 [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period			3,000,000
Equity Incentive Plan 2013 [Member] | Founding Stock Holder [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period	3,500,000
Equity Incentive Plan 2013 [Member] | Consultant One [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period	54,404
Equity Incentive Plan 2013 [Member] | Founding Stock Holder and Consultant One [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period	10 years
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price	$1.75
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage	100.00%
Equity Incentive Plan 2013 [Member] | Consultant Two [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period	250,000
Equity Incentive Plan 2013 [Member] | Consultant Three [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period	300,000
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period	10 years
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price	$1
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage	20.00%
Share Based Compensation Arrangement By Share Based Payment Award Options Vested Period	4 years
Equity Incentive Plan 2013 [Member] | One Employee [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period				20,000			50,000
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period				10 years			10 years
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price				$0.60			$1.24
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage				20.00%			20.00%
Equity Incentive Plan 2013 [Member] | Four Directors [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period	1,050,000
Equity Incentive Plan 2013 [Member] | Four Directors And Consultant Two [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period	10 years
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price	$1
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage	20.00%
Share Based Compensation Arrangement By Share Based Payment Award Options Vested Period	5 years

Common_and_Preferred_Stock_Res2

Common and Preferred Stock Reserved for Future Issuances: (Details)	Dec. 31, 2014
Class of Stock [Line Items]
Common Stock Reserved	30,743,974
Preferred Stock Reserved	1,325,000
Common Stock Warrant Outstanding [Member]
Class of Stock [Line Items]
Common Stock Reserved	286,772
Preferred Stock Reserved	0
Preferred Stock Warrant Outstanding [Member]
Class of Stock [Line Items]
Common Stock Reserved	1,325,000
Preferred Stock Reserved	1,325,000
Common Stock Option Outstanding [Member]
Class of Stock [Line Items]
Common Stock Reserved	7,769,202
Preferred Stock Reserved	0
Conversion of Series A Preferred Stock [Member]
Class of Stock [Line Items]
Common Stock Reserved	21,363,000
Preferred Stock Reserved	0

Subsequent_Events_Details_Text

Subsequent Events: (Details Textual) (USD $)	1 Months Ended	12 Months Ended	1 Months Ended	3 Months Ended	12 Months Ended	0 Months Ended
	Feb. 28, 2013	Dec. 31, 2014	Feb. 28, 2015	Mar. 31, 2015	Sep. 30, 2015	Feb. 09, 2015	Mar. 26, 2015
Subsequent Event [Line Items]
Conversion of Stock, Shares Converted		1,637,000
Technology Services Costs	$266,666
Blanchette Rockefeller Neurosciences Institute [Member]
Subsequent Event [Line Items]
Technology Services Costs		600,000
Payments for Fees		400,000
Series A Preferred Stock [Member]
Subsequent Event [Line Items]
Conversion of Stock, Shares Converted		1,637,000
Subsequent Event [Member]
Subsequent Event [Line Items]
Technology Services Costs			600,000
Reimbursement Of Third Party Expense			-150,000
Subsequent Event [Member] | Investor [Member]
Subsequent Event [Line Items]
Stock Issued During Period, Shares, Conversion of Convertible Securities				2,580,606
Class of Warrant or Right, Number of Securities Called by Warrants or Rights							180,558
Subsequent Event [Member] | Warrant Holder [Member]
Subsequent Event [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights						1,325,000
Subsequent Event [Member] | Blanchette Rockefeller Neurosciences Institute [Member]
Subsequent Event [Line Items]
Due to Other Related Parties			-2,400,000
Other Cost of Services (per month)					-200,000
Payments for Fees				200,000
Subsequent Event [Member] | Series A Preferred Stock [Member] | Investor [Member]
Subsequent Event [Line Items]
Conversion of Stock, Shares Converted				2,580,606
Subsequent Event [Member] | Series A Preferred Stock [Member] | Warrant Holder [Member]
Subsequent Event [Line Items]
Conversion of Stock, Shares Converted						1,325,000